Anne E. Borgman-Hagey

3.7k total citations
7 papers, 119 citations indexed

About

Anne E. Borgman-Hagey is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anne E. Borgman-Hagey has authored 7 papers receiving a total of 119 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 4 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anne E. Borgman-Hagey's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver physiology and pathology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Anne E. Borgman-Hagey is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Liver physiology and pathology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Anne E. Borgman-Hagey collaborates with scholars based in Taiwan, United Kingdom and United States. Anne E. Borgman-Hagey's co-authors include Ann‐Lii Cheng, Ghassan K. Abou‐Alfa, Tim Meyer, Robin Kate Kelley, Anthony B. El-Khoueiry, Philippe Merle, Jean‐Frédéric Blanc, Baek‐Yeol Ryoo, Lorenza Rimassa and Heinz‐Josef Klümpen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Anne E. Borgman-Hagey

7 papers receiving 118 citations

Peers

Countries citing papers authored by Anne E. Borgman-Hagey

Since Specialization

Citations

This map shows the geographic impact of Anne E. Borgman-Hagey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne E. Borgman-Hagey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne E. Borgman-Hagey more than expected).

Fields of papers citing papers by Anne E. Borgman-Hagey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne E. Borgman-Hagey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne E. Borgman-Hagey. The network helps show where Anne E. Borgman-Hagey may publish in the future.

Co-authorship network of co-authors of Anne E. Borgman-Hagey

This figure shows the co-authorship network connecting the top 25 collaborators of Anne E. Borgman-Hagey. A scholar is included among the top collaborators of Anne E. Borgman-Hagey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne E. Borgman-Hagey. Anne E. Borgman-Hagey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC) 2019 ·Annals of Oncology ·Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek‐Yeol Ryoo, Philippe Merle, (unknown), Jean‐Frédéric Blanc, Ho Yeong Lim, Albert Tran, Anne E. Borgman-Hagey, D O Clary, (unknown), Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	12
2	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. 2018 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Yen‐Hsun Chen, Joong‐Won Park, Jean‐Frédéric Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vincenzo Dadduzio, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley	8
3	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. 2018 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Joong‐Won Park, Jean‐Frédéric Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vincenzo Dadduzio, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley	69
4	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). 2015 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Tim Meyer, Anthony B. El-Khoueiry, Masafumi Ikeda, Hoo G. Chun, Junji Furuse, Jennifer J. Knox, Takuji Okusaka, Jerry Ping, Anne E. Borgman-Hagey, Robin Kate Kelley	13
5	4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial 2015 ·European Journal of Cancer ·Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, (unknown), Thomas E. Hutson, Beat Roth, Katriina Peltola, (unknown), D.Y.C. Heng, Manuela Schmidinger, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, (unknown), Robert J. Motzer	2
6	Phase 3 Randomized, Double-Blind, Controlled Study of Cabozantinib (Xl184) Vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib (Celestial) (Nct01908426) 2014 ·Annals of Oncology ·G.K. Abou-Alfa, Ann‐Lii Cheng, Tim Meyer, Anthony B. El-Khoueiry, Masafumi Ikeda, Honggu Chun, Junji Furuse, (unknown), Takuji Okusaka, Massimo Colombo, Philippe Merle, Armando Santoro, Damien Gallagher, Ewa Janczewska, Jörg Trojan, Heinz‐Josef Klümpen, (unknown), Jerry Ping, Anne E. Borgman-Hagey, Robin Kate Kelley	9
7	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). 2014 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Tim Meyer, Anthony B. El-Khoueiry, Masafumi Ikeda, Hoo G. Chun, Sandrine Faivre, Junji Furuse, Jennifer J. Knox, Takuji Okusaka, Jerry Ping, Anne E. Borgman-Hagey, Robin Kate Kelley	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact